TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05922072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric aspiration for measurement of Residual Gastric Volume
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasogastric aspiration for measurement of Residual Gastric Volume
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Aspiration for Measurement of Gastric pH
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasogastric Aspiration for Measurement of Gastric pH
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
Study: NCT06325293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pfizer®
Description: Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control comparator arm: 5 days of placebo
Study: NCT06242639

Intervention type: OTHER
Intervention: Clinical examination
Description: clinic and radiographic evaluation
Study: NCT06074133

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Undergo blood draw
Study: NCT06080646

Intervention type: OTHER
Intervention: cross-sectional MRI and EEG assessments (NO INTERVENTION)
Description: n/a there is no intervention in this observational study

Intervention type: OTHER
Intervention: cross-sectional MRI and EEG assessments (NO INTERVENTION)
Description: n/a there is no intervention in this observational study
Study: NCT06778564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 100 mg/mL Oral Solution
Description: Daily dose 1000mg, taken as 500mg (5ml) b.i.d for 6 weeks. For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5ml b.i.d for 6 weeks; For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
Study: NCT06074133

Intervention type: PROCEDURE
Intervention: Chest Computed Tomography
Description: Undergo standard of care chest Computed Tomography
Study: NCT05061654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam IV
Description: Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
Study: NCT04502394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
Study: NCT04902651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HM242-Gel
Description: HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrasite Gel
Description: HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
Study: NCT04919460

Intervention type: OTHER
Group type: OTHER
Intervention: clinical observation combined with pathological biopsy
Description: Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy
Description: (2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
Study: NCT06477679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: • Furlow with buccinators myomucosal flap
Description: • Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: • Two flap palatoplasty as von langenbeck technique
Description: • Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back
Study: NCT05137600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is a sensitive CYP3A index substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
Study: NCT06455306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-polishing with erythritol at different time points
Description: The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Air-polishing with erythritol
Description: The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.
Study: NCT05248503

Intervention type: BEHAVIORAL
Intervention: Complex Care Training of Hereditary Epidermolysis Bullosa
Description: Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
Study: NCT05890469

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Zirconia surface implant and guided bone regeneration
Description: The Straumann® PURE Ceramic Implant System is made from 100 % yttria-stabilized zirconia. Its surface features a topography characterized by macro- and micro-roughness to offer a structure for cell attachment and the osseointegration of this surface has been successfully proven. Owing to the increasing aesthetic standards in the field of implant dentistry and the concerns on sensitivity to titanium, there has been a growing interest towards metal-free implant rehabilitation.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Hydrophilic titanium surface implant and guided bone regeneration
Description: The Straumann® Standard Plus (SP) Implant is a Soft Tissue Level Implant with a smooth neck section of 1.8 mm. It has a fundamentally improved hydrophilic surface chemistry (SLActive®) which accelerates the osseointegration process in the early healing phase.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).
Study: NCT06390267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sparrow Hawk (Active)
Description: Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sparrow Hawk (Active)
Description: Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sparrow Hawk (Sham)
Description: Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sparrow Hawk (Sham)
Description: Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.
Study: NCT05889442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Description: Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
Study: NCT04720716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 IV d1, Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: sintilimab IV d1, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400mg po
Study: NCT05400109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UF-KURE19 CAR-T cells
Description: UF-KURE19 cells are initially generated from a starting autologous apheresis sample. T cells are activated and transduced with Kure19 lentiviral vector that consists of a 3rd generation vector with an scFV (FMC63) that targets CD19. The product is harvested at 17-20hr after culture and cryopreserved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The mechanism of action is thought to involve cross-linking of tumor cell DNA
Study: NCT05977985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotator interval hydro-dissection with dextrose 5%
Description: Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotator interval hydro-dissection with corticosteroid solution
Description: Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
Study: NCT06031714

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva sampling
Description: HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva sampling
Description: HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva sampling
Description: HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out.

Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: V2 and/or V3

Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: V2 and/or V3

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination
Description: V2 and/or V3

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination
Description: V2 and/or V3
Study: NCT05352854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% pilocarpine eye drops
Description: Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% pilocarpine eye drops
Description: Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% pilocarpine eye drops
Description: Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% pilocarpine eye drops
Description: Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
Study: NCT06501027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Self Compassion
Description: The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Self Compassion
Description: The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of
Study: NCT06508320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083
Description: IM injection in a deltoid muscle.
Study: NCT05561491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: Oncolytic virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: Oncolytic virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Anti PD-1
Study: NCT05469516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System [Ulthera, Inc.]
Description: The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~- Non-invasive treatment of Axillary Hyperhidrosis
Study: NCT05585528

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional or surgical management in 1st intention
Description: Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
Study: NCT05607030

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VT-X7 Treatment System
Description: Seven-day local antibiotic irrigation (alternating vancomycin hydrochloride and tobramycin sulfate) via the temporary VT-X7 Knee or Hip Spacer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis.
Study: NCT04083170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo UCBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo UCBT
Study: NCT05607030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC Antibiotics
Description: Administration of at least 6 weeks of systemic antibiotics post-Stage 1 surgery followed by a 2-week antibiotic holiday before the Stage 2 surgery. After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Antibiotics
Description: After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
Study: NCT05048797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab Deruxtecan administered by intravenous infusion
Study: NCT06508320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083
Description: IM injection in a deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083
Description: IM injection in a deltoid muscle.
Study: NCT05652205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Capsule; oral
Study: NCT05048797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed administered by intravenous infusion
Study: NCT05652205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Linaclotide
Description: Capsule; oral
Study: NCT05393024

Intervention type: DRUG
Intervention: Belantamab mafodotin
Description: MMRR patients included in Named Patient Program e Expanded Access Program
Study: NCT06079073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional therapy with autofeedback
Description: Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
Study: NCT04259788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AHEI diet
Description: Main intervention is the consumption of an AHEI diet for 12 weeks.
Study: NCT06571669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Neuromodulation